TWi gets approval for protocol of Phase II trial of AC-201 in US and Taiwan
Patient enrollment in the Phase II clinical trial will be initiated as soon as possible, according to the company. AC-201 has shown the ability to inhibit the production
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
Under the deal, the two parties will establish scalable processes for manufacturing recombinant adeno-associated viral (rAAV) vector products using current good manufacturing practices (cGMP). The deal will combine